BERKELEY, Calif., June 7 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX - News) announced that enrollment in the Dynavax Allergic Rhinitis TOLAMBA Trial (DARTT) has exceeded expectations relative to the speed and number of study subjects. More than 700 subjects were enrolled in the study in less than eight weeks, prompting Dynavax to close enrollment early. Enrollment in the DARTT study has been completed and all subjects have been randomized. The company believes that strong investigator and patient interest in TOLAMBA as a potentially disease-modifying allergy intervention, as well as TOLAMBA's safety profile, were important factors in accelerating enrollment in the trial.
